Duration of vasomotor symptoms in middle-aged women: a longitudinal study

被引:105
作者
Col, Nananda F. [1 ]
Guthrie, Janet R. [2 ]
Politi, Mary [3 ]
Dennerstein, Lorraine [2 ]
机构
[1] Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04101 USA
[2] Univ Melbourne, Off Gender & Hlth, Dept Psychiat, Melbourne, Vic 3010, Australia
[3] Brown Med Sch, Dept Behav & Prevent Med, Providence, RI USA
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2009年 / 16卷 / 03期
基金
英国医学研究理事会;
关键词
Menopause; Hot flushes; Vasomotor symptoms; Symptom duration; Longitudinal studies; ESTROGEN PLUS PROGESTIN; HEALTHY POSTMENOPAUSAL WOMEN; MENOPAUSAL TRANSITION; CARDIOVASCULAR-DISEASE; HORMONE-THERAPY; POPULATION; MIDLIFE; RISK; LIFE;
D O I
10.1097/gme.0b013e31818d414e
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Vasomotor symptoms adversely affect the quality of life and functional status of most women during the menopausal transition, but little is known about how long these symptoms last. The most effective treatment, hormone therapy (HT), carries risks and benefits that depend on the timing and duration of use. In this study we sought to estimate the duration of vasomotor symptoms in a longitudinal study. Methods: We reanalyzed primary data from 438 women in the longitudinal cohort of the population-based Melbourne Women's Midlife Health Project. Two hundred and five women who had completed 13 years of follow-up were included in the analyses. The onset and cessation of vasomotor symptoms were reported, stratifying analyses according to ever use of HT. Symptom duration was calculated as the time between the first and last bothersome hot flush reported. Results: The mean (SD) duration of bothersome menopausal symptoms for women who completed 13 years of follow-up and who never used HT was estimated to be 5.2 (3.8) years (median, 4 years). If women who used HT were included, the mean (SD) duration was 5.5 (4.0) years (median, 4 years). The estimated duration of symptoms varied according to the duration of longitudinal follow-up, with a mean estimate of 3.4 years (median, 3 years) when only 8 years of follow-up data were analyzed. The only factor associated with duration of hot flushes was regular exercise-more exercise was associated with shorter symptom duration. Conclusions: The average duration of vasomotor symptoms in this sample is more than 5 years, substantially longer than had been previously reported.
引用
收藏
页码:453 / 457
页数:5
相关论文
共 34 条
[1]  
*AM COLL OBST GYN, 2004, OBSTET GYNECOL S, V104, pS1
[2]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[3]  
[Anonymous], ANN NY ACAD SCI
[4]   Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups [J].
Avis, NE ;
Stellato, R ;
Crawford, S ;
Bromberger, J ;
Ganz, P ;
Cain, V ;
Kagawa-Singer, M .
SOCIAL SCIENCE & MEDICINE, 2001, 52 (03) :345-356
[5]   Ethnic differences in use of complementary and alternative medicine at midlife: Longitudinal results from SWAN participants [J].
Bair, YA ;
Gold, EB ;
Greendale, GA ;
Sternfeld, B ;
Adler, SR ;
Azari, R ;
Harkey, M .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2002, 92 (11) :1832-1840
[6]   THE ENDOCRINOLOGY OF THE MENOPAUSAL TRANSITION - A CROSS-SECTIONAL STUDY OF A POPULATION-BASED SAMPLE [J].
BURGER, HG ;
DUDLEY, EC ;
HOPPER, JL ;
SHELLEY, JM ;
GREEN, A ;
SMITH, A ;
DENNERSTEIN, L ;
MORSE, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3537-3545
[7]   Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial [J].
Cauley, JA ;
Robbins, J ;
Chen, Z ;
Cummings, SR ;
Jackson, RD ;
LaCroix, AZ ;
LeBoff, M ;
Lewis, CE ;
McGowan, J ;
Neuner, J ;
Pettinger, M ;
Stefanick, ML ;
Wactawski-Wende, J ;
Watts, NB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (13) :1729-1738
[8]   Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial [J].
Chlebowski, RT ;
Hendrix, SL ;
Langer, RD ;
Stefanick, ML ;
Gass, M ;
Lane, D ;
Rodabough, RJ ;
Gilligan, MA ;
Cyr, MG ;
Thomson, CA ;
Khandekar, J ;
Petrovitch, H ;
McTiernan, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3243-3253
[9]   The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms [J].
Col, NF .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (12) :1411-1411
[10]   Short-term menopausal hormone therapy for symptom relief - An updated decision model [J].
Col, NF ;
Weber, G ;
Stiggelbout, A ;
Chuo, J ;
D'Agostino, R ;
Corso, P .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (15) :1634-1640